Amptron’s R &D is based out of the US and this will enable Max to obtain US and other global certifications. Max will retain the right to market, sell and distribute the products in India.
The newest entrant from the company is the MOSS 1800F with an oxygen flow rate of 180 LPM or 10.8 Nm3/hour
The focus is on wellness and personal care products
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
The investment is part of the group's digital health initiatives, to foster affordable access to world-class technology and an innovation-led healthcare ecosystem in India
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
The trial will be conducted across eight sites in Maharashtra
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
The company has been sold to Shinshin Pharmaceuticals
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
Subscribe To Our Newsletter & Stay Updated
